Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation
Jian Yu, … , Steven P. Briggs, Thomas J. Kipps
Jian Yu, … , Steven P. Briggs, Thomas J. Kipps
Published December 21, 2015
Citation Information: J Clin Invest. 2016;126(2):585-598. https://doi.org/10.1172/JCI83535.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 75

Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation

  • Text
  • PDF
Abstract

Evolutionarily conserved receptor tyrosine kinase–like orphan receptor-1 and -2 (ROR1/2) are considered distinct receptors for Wnt5a and are implicated in noncanonical Wnt signaling in organogenesis and cancer metastasis. We found that Wnt5a enhanced proliferation and migration of chronic lymphocytic leukemia (CLL) cells and that these effects were blocked by the humanized anti-ROR1 mAb cirmtuzumab (UC-961). Treatment of CLL cells with Wnt5a induced ROR1 to oligomerize with ROR2 and recruit guanine exchange factors (GEFs), which activated Rac1 and RhoA; siRNA-mediated silencing of either ROR1 or ROR2 or treatment with UC-961 inhibited these effects. Using the ROR1-deficient CLL cell line MEC1, we demonstrated that ectopic ROR1 expression induced ROR1/ROR2 heterooligomers, which recruited GEFs, and enhanced proliferation, cytokine-directed migration, and engraftment potential of MEC1 cells in immune-deficient mice. Notably, treatment with UC-961 inhibited engraftment of ROR1+ leukemia cells in immune-competent ROR1-transgenic mice. Molecular analysis revealed that the extracellular Kringle domain is required for ROR1/ROR2 heterooligomerization and the cysteine-rich domain or intracellular proline-rich domain is required for Wnt5a-induced recruitment of GEFs to ROR1/ROR2. This study identifies an interaction between ROR1 and ROR2 that is required for Wnt5a signaling that promotes leukemia chemotaxis and proliferation.

Authors

Jian Yu, Liguang Chen, Bing Cui, George F. Widhopf II, Zhouxin Shen, Rongrong Wu, Ling Zhang, Suping Zhang, Steven P. Briggs, Thomas J. Kipps

×

Figure 7

Structural domains of ROR1 required for migration or proliferation.

Options: View larger image (or click on image) Download as PowerPoint
Structural domains of ROR1 required for migration or proliferation.
(A) ...
(A) Mean numbers of MEC1 (blue circles), MEC1-ROR1 (red squares), or MEC1 cells expressing each of the truncated forms of ROR1 (colors indicated in the legend) in triplicate wells at the days indicated below the graph. (B) Mean numbers of MEC1-ROR1 cells cultured with Ctrl-IgG (blue squares), UC-961 (red triangles), or anti-Wnt5a (green inverted triangles) in triplicate wells at the times indicated below. (C) Bars indicate the mean proportions of MEC1 (blue), MEC1-ROR1 (red), or MEC1 cells transfected with each of the truncated forms of ROR1 (various colors, as indicated in the legend) migrating with (+) or without (–) CCL21, as indicated at the bottom. (D) Bars depict the mean proportions of MEC1-ROR1 cells migrating with (+) or without (–) CCL21 in the presence of Ctrl-IgG (blue bars), UC-961 (green bars), or anti-Wnt5a (red bars). Data in panels A–D are shown as mean ± SEM. *P < 0.05; **P < 0.01, as determined by 2-tailed Student’s t test. (E) Diagram of model for how Wnt5a can enhance proliferation and migration by inducing formation of a ROR1/ROR2 heterooligomer, which recruits GEFs that in turn activate Rac1 and RhoA.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 10 news outlets
Posted by 3 X users
Referenced in 10 patents
168 readers on Mendeley
1 readers on CiteULike
See more details